TLSA earnings: next report 2026-09-18, real EPS beat/miss history, analyst consensus Buy, P/E -4.12. Updated 2026-07-23.
Tiziana Life Sciences (TLSA) Research Hub
Tiziana Life Sciences (TLSA) trades on NASDAQ, BM in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.96 USD (-1.71%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.12, market cap 0.06B. This hub links to the full technical, earnings and options research available for TLSA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, BM |
| Last close | 0.96 USD (-1.71%) |
| 52-week range | 0.8663 USD – 1.38 USD |
| Trend regime | Range |
| 14-day RSI | 46.6 (Neutral) |
| Trailing P/E | -4.12 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-18 |
Available research for TLSA
Covered Call on TLSA: how it works, illustrative setup around the real 0.96 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TLSA: how it works, illustrative setup around the real 0.96 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TLSA: how it works, illustrative setup around the real 0.96 USD price, max profit/loss, breakeven and when to use it. Educational.
TLSA technical analysis: range, last 0.96 USD, RSI 46.6, 52w range 0.8663 USD–1.38 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TLSA in?
Tiziana Life Sciences (TLSA) is classified under Healthcare (Biotechnology), listed on NASDAQ, BM.
Is TLSA in an uptrend or downtrend?
As of 2026-09-11, TLSA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TLSA's trailing P/E ratio?
TLSA's trailing P/E is -4.12, with a market cap of 0.06B. See the earnings research page for full valuation detail.
When does TLSA next report earnings?
TLSA is next scheduled to report earnings on 2026-09-18, with a consensus EPS estimate of -0.07918 USD.